RxDoctor Payments DataLook up a doctor →

Dennis Slater, MD

Hematology · Norwich, CTNPI 1447235486

Payments from drug & device makers

$3,851,326in general payments, 2019–2025

Across 958 payments — averaging $4020.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medivation LLC.$1M
  • Pfizer$907K
  • Seagen Inc.$560K
  • Genentech, Inc.$432K
  • Amgen$178K
  • AstraZeneca$106K
  • plus $631K from 54 others
$6,237in research payments, 2019–2025

Across 8 payments — averaging $779.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$5K
  • Eli Lilly$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medivation LLC.43$1,037,159
Pfizer89$907,005
Seagen Inc.92$559,622
Genentech, Inc.118$432,293
Amgen15$177,733
AstraZeneca(2 entities)23$106,432
Janssen Research & Development, LLC31$102,911
EMD Serono, Inc.47$87,956
Merck34$80,631
Jazz Pharmaceuticals Inc.68$75,737
E.r. Squibb & Sons, L.L.C.29$74,665
Astrazeneca UK Limited9$56,341
United Therapeutics Corporation5$44,626
Mirati Therapeutics, Inc.30$41,731
Novartis39$23,939
Eli Lilly1$16,779
Array Biopharma Inc12$11,610
F. Hoffmann-la Roche AG3$8,427
Johnson & Johnson(2 entities)46$850
Astellas Pharma US Inc18$427
Bristol Myers Squibb19$377
Clovis Oncology, Inc.1$375
Sanofi17$294
Gilead(2 entities)13$280
Genentech USA, Inc.16$260
Lilly USA, LLC9$233
Eisai Inc.11$221
AbbVie12$215
Pharmacyclics LLC, An Abbvie Company10$214
Incyte Corporation12$196
Bayer7$183
Rigel Pharmaceuticals, Inc.7$119
GSK4$110
ADC Therapeutics America, Inc.4$104
Blueprint Medicines Corporation4$103
Ipsen Biopharmaceuticals, Inc4$88
Exelixis Inc.4$80
Boehringer Ingelheim5$72
Daiichi Sankyo Inc.4$61
Genmab U.S., Inc.2$60
Takeda Pharmaceuticals U.S.A., Inc.3$59
Karyopharm Therapeutics Inc.3$59
Coherus Oncology, Inc.2$51
Geron Corporation2$50
Sumitomo Pharma America, Inc.2$48
Epizyme, Inc.3$48
Regeneron Healthcare Solutions, Inc.2$45
Dendreon Pharmaceuticals LLC1$35
Puma Biotechnology, Inc.2$33
Pharmacosmos Therapeutics Inc.1$32
Beigene USA, Inc.2$30
Advanced Accelerator Applications1$25
Servier Pharmaceuticals LLC1$24
Agios Pharmaceuticals, Inc.1$22
Pharmaessentia USA Corporation1$20
CTI Biopharma Corp.1$20
Tesaro, Inc.1$19
Azurity Pharmaceuticals, Inc.1$19
Recordati_rare_diseases_inc.1$19
Foundation Medicine, Inc.1$19

How this compares

$3,851,326 in reported general payments places this provider in the 95th percentile of 24 hematology providers in Connecticut.

See all hematology providers in Connecticut →

Medicare billing

Part B allowed, 2024
$41,003
Medicare patients
96
Services billed
2,891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology in Norwich

See the full list for Connecticut →

Where these figures come from

Is this you, or does something look wrong? →